
AbbVie and IGI Announce Exclusive Worldwide Licensing Deal for First-in-Class Trispecific Antibody ISB 2001
AbbVie and IGI Therapeutics Sign Exclusive Global Licensing Agreement for Trispecific Antibody ISB 2001 AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive global licensing agreement for ISB 2001, IGI’s…











